Improvements to the U.S. supply chain are needed to reduce shortages and protect American patients. Industry, academia, ...

QurAlis’ Kasper Roet describes the regulatory hurdles facing the RNA research space in the U.S. and why many companies are pursuing clinical work elsewhere.

QurAlis founder Kasper Roet explains how precision medicine can revolutionize neurogenerative disease therapeutics.